Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma
dc.contributor.author | Cardona-Mendoza, Andrés Felipe | |
dc.contributor.author | Rojas Puentes, Leonardo | |
dc.contributor.author | Wills, Beatriz | |
dc.contributor.author | Bernal, Laura | |
dc.contributor.author | Ruiz-Patiño, Alejandro | |
dc.contributor.author | Arrieta, Oscar | |
dc.contributor.author | Jiménez Hakim, Enrique | |
dc.contributor.author | Hakim, Fernando | |
dc.contributor.author | Mejía, Juan Armando | |
dc.contributor.author | Useche, Nicolás | |
dc.contributor.author | Bermúdez, Sonia | |
dc.contributor.author | Carranza Isaza, Hernán | |
dc.contributor.author | Vargas Báez, Carlos Alberto | |
dc.contributor.author | Otero, Jorge | |
dc.contributor.author | Mayor, Luis Carlos | |
dc.contributor.author | Ortíz, León Darío | |
dc.contributor.author | Franco, Sandra | |
dc.contributor.author | Ortíz, Carlos | |
dc.contributor.author | Gil-Gil, Miguel | |
dc.contributor.author | Balaña, Carmen | |
dc.contributor.author | Zatarain-Barrón, Zyanya Lucia | |
dc.contributor.orcid | Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471] | |
dc.contributor.orcid | Carranza Isaza, Hernán [0000-0002-3593-7405] | |
dc.contributor.orcid | Vargas Báez, Carlos Alberto [0000-0002-6076-8260] | |
dc.contributor.orcid | Rojas Puentes, Leonardo [0000-0002-7865-5424] | |
dc.date.accessioned | 2020-05-18T06:04:54Z | |
dc.date.available | 2020-05-18T06:04:54Z | |
dc.date.issued | 2018 | |
dc.description.abstractenglish | Epilepsy is a common symptom in patients with glioblastoma (GB). 213 patients with GB from RedLANO follow-up registry were included. All patients underwent surgery, if feasible, followed by chemoradiation based on temozolomide (Stupp platform). Information was recorded regarding demographics, seizure timing, anti-epileptic drugs (AEDs), dosage, time to next seizure, total seizures in 6 months, and main side effects of AEDs. The relationship between epilepsy treatment and overall survival (OS) was evaluated. Mean age was 53 years old and 56.8% were male. Seventy-eight patients (37%) were treated with levetiracetam (LEV), 27% were given another AED and 36% did not require any AED. Choice of AED was not associated with age (p = 0.67), performance status (p = 0.24) or anatomic tumor site (p = 0.34). Seizures and AED requirement were greater in those having primary GB (p = 0.04). After starting an AED, the mean time until next crisis was 9.9 days (SD ± 6.3), which was shorter in those receiving LEV (p = 0.03); mean number of seizures during the first 3 and 6 months were 2.9 and 4, respectively. Most patients treated with LEV (n = 46) required less than two medication adjustments compared to those treated with other AEDs (p = 0.02). Likewise, less patients exposed to LEV required a coadjuvant drug (p = 0.04). Additionally, patients receiving LEV had significantly less adverse effects compared to patients treated with another AED. OS was significantly higher in the group treated with LEV compared to other AEDs (25.5 vs. 17.9 months; p = 0.047). Patients treated with LEV had better seizure control and longer OS compared to other AEDs. | eng |
dc.format.mimetype | application/pdf | |
dc.identifier.doi | https://doi.org/10.1007/s11060-017-2660-0 | |
dc.identifier.issn | 1573-7373 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12495/2900 | |
dc.language.iso | eng | |
dc.publisher | Springer | spa |
dc.publisher.journal | Journal of Neuro-Oncology | spa |
dc.relation.ispartofseries | Journal of Neuro-Oncology, 1573-7373, Vol 136, Num 2, 2018, pag 363-371 | spa |
dc.relation.uri | https://link.springer.com/article/10.1007/s11060-017-2660-0 | |
dc.rights.creativecommons | 2018 | |
dc.rights.local | Acceso cerrado | spa |
dc.subject.decs | Anticonvulsivantes | spa |
dc.subject.decs | Evaluación de medicamentos | spa |
dc.subject.decs | Pirrolidinonas | spa |
dc.subject.keywords | Efficacy | spa |
dc.subject.keywords | Safety | spa |
dc.subject.keywords | Antiepileptic drugs | spa |
dc.subject.keywords | Hispanic | spa |
dc.subject.keywords | Glioblastoma | spa |
dc.title | Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma | spa |
dc.title.translated | Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma | spa |
dc.type | article | spa |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | |
dc.type.local | artículo | spa |
Archivos
Bloque original
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- Cardona, Andrés F..pdf
- Tamaño:
- 1.15 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: